Baird Medical Announces Preliminary H1 Revenue Results Of $13.1M, Up 13.8% YoY

Benzinga
2024-10-11

Total revenues increased to US$13.1 million, representing 13.8% year-over-year growthNet income reached US$4.4 million, representing 85.8% year-over-year growth

GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced its preliminary financial results for the six months ended June 30, 2024 (the "First Half of 2024").

First Half of 2024 Financial Highlights

  • Total revenues reached US$13.1 million, representing an increase of 13.8% from US$11.5 million in the same period of 2023.
  • Gross profit increased by 20.9% to US$11.5 million from US$9.5 million in the first half of 2023.
  • Operating income was US$5.1 million, representing an increase of 70.0% from US$3.0 million in the same period of 2023.
    • Net income increased by 85.8% to US$4.4 million from US$2.4 million in the first half of 2023.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10